PureTech News

Press releases
Press Releases - 2026-05-13
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
Continue
Press Releases - 2026-05-01
Seaport
PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Continue
Press Releases - 2026-04-29
Other
PureTech Announces Annual Results for Year Ended December 31, 2025
Continue
Press Releases - 2026-04-29
Other
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
Continue
Press Releases - 2026-04-27
Seaport
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Continue
Press Releases - 2026-04-22
Gallop Oncology – LYT-200
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Continue
Press Releases - 2026-04-13
Other
PureTech Health plc Notice of Results
Continue
Press Releases - 2026-04-13
Seaport
PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering
Continue
Press Releases - 2026-04-02
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Continue
Press Releases - 2026-04-02
Seaport
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Continue
Displaying 1 - 10 of 245

Sign up for email alerts

To receive news as it is released, please sign up.

@PureTechH